Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

Abnormalities of prefrontal cortical function are prominent features of schizophrenia and have been associated with genetic risk, suggesting that susceptibility genes for schizophrenia may impact on the molecular mechanisms of prefrontal function. A potential susceptibility mechanism involves regulation of prefrontal dopamine, which modulates the response of prefrontal neurons during working memory. We examined the relationship of a common functional polymorphism (Val108/158 Met) in the catechol-O-methyltransferase (COMT) gene, which accounts for a 4-fold variation in enzyme activity and dopamine catabolism, with both prefrontally mediated cognition and prefrontal cortical physiology. In 175 patients with schizophrenia, 219 unaffected siblings, and 55 controls, COMT genotype was related in allele dosage fashion to performance on the Wisconsin Card Sorting Test of executive cognition and explained 4% of variance (P = 0.001) in frequency of perseverative errors. Consistent with other evidence that dopamine enhances prefrontal neuronal function, the load of the low-activity Met allele predicted enhanced cognitive performance. We then examined the effect of COMT genotype on prefrontal physiology during a working memory task in three separate subgroups (n = 11–16) assayed with functional MRI. Met allele load consistently predicted a more efficient physiological response in prefrontal cortex. Finally, in a family-based association analysis of 104 trios, we found a significant increase in transmission of the Val allele to the schizophrenic offspring. These data suggest that the COMT Val allele, because it increases prefrontal dopamine catabolism, impairs prefrontal cognition and physiology, and by this mechanism slightly increases risk for schizophrenia.

[1]  P. Goldman-Rakic,et al.  Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Coppola,et al.  Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. , 2000, Cerebral cortex.

[3]  Tom H. Lindner,et al.  Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus , 2000, Nature Genetics.

[4]  Richard Coppola,et al.  Effects of Dextroamphetamine on Cognitive Performance and Cortical Activation , 2000, NeuroImage.

[5]  M. Egan,et al.  Relative risk of attention deficits in siblings of patients with schizophrenia. , 2000, The American journal of psychiatry.

[6]  Tyrone D. Cannon,et al.  The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. , 2000, American journal of human genetics.

[7]  R. Murray,et al.  Family-based linkage disequilibrium mapping using SNP marker haplotypes: application to a potential locus for schizophrenia at chromosome 22q11 , 2000, Molecular Psychiatry.

[8]  W. Honer,et al.  Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. , 2000, Science.

[9]  P. McGuffin,et al.  Linkage and associated studies of schizophrenia. , 2000, American journal of medical genetics.

[10]  A. Carlsson,et al.  Network interactions in schizophrenia — therapeutic implications , 2000, Brain Research Reviews.

[11]  J. Mallet,et al.  Linkage disequilibrium on the COMT gene in French schizophrenics and controls. , 1999, American journal of medical genetics.

[12]  A. Sampson,et al.  Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.

[13]  Kenneth K Kidd,et al.  Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles , 1999, Biological Psychiatry.

[14]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[15]  E. Martin,et al.  Sibling-based tests of linkage and association for quantitative traits. , 1999, American journal of human genetics.

[16]  Steven Warach,et al.  Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI , 1999, Biological Psychiatry.

[17]  R. Weinshilboum,et al.  Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. , 1999, Annual review of pharmacology and toxicology.

[18]  R. Quatrano.  Genomics , 1998, Plant Cell.

[19]  A D Roses,et al.  Apolipoprotein E and ALzheimer's Disease: The Tip of the Susceptibility Iceberg , 1998, Annals of the New York Academy of Sciences.

[20]  J. Cohen,et al.  Functional hypofrontality and working memory dysfunction in schizophrenia. , 1998, The American journal of psychiatry.

[21]  D. Pfaff,et al.  Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Goldman-Rakic,et al.  The cerebral cortex: a case for a common site of action of antipsychotics. , 1998, Trends in pharmacological sciences.

[23]  Allan I. Levey,et al.  Dopamine Axon Varicosities in the Prelimbic Division of the Rat Prefrontal Cortex Exhibit Sparse Immunoreactivity for the Dopamine Transporter , 1998, The Journal of Neuroscience.

[24]  D. Housman,et al.  Identification of Sequence Variants and Analysis of the Role of the Catechol-O-Methyl-Transferase Gene in Schizophrenia Susceptibility , 1998, Biological Psychiatry.

[25]  T. Terao,et al.  Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics , 1998, Neuroscience Letters.

[26]  J. Seamans,et al.  D1 Receptor Modulation of Hippocampal–Prefrontal Cortical Circuits Integrating Spatial Memory with Executive Functions in the Rat , 1998, The Journal of Neuroscience.

[27]  S. Sesack,et al.  Dopamine axons in primate prefrontal cortex: specificity of distribution, synaptic targets, and development. , 1998, Advances in pharmacology.

[28]  D. Bell,et al.  An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. , 1997, Cancer research.

[29]  R. Murray,et al.  Catechol‐O‐methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families , 1997, Psychiatric genetics.

[30]  H. Hwu,et al.  Association study of NlaIII and MspI genetic polymorphisms of catechol-O-methyltransferase gene and susceptibility to Schizophrenia , 1997, Biological Psychiatry.

[31]  Edward E. Smith,et al.  Temporal dynamics of brain activation during a working memory task , 1997, Nature.

[32]  H. Lachman,et al.  Lack of association of functional cathechol-O-methyltransferase gene polymorphism in schizophrenia , 1997, Biological Psychiatry.

[33]  L Kruglyak,et al.  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. First,et al.  User's guide for the structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version , 1997 .

[35]  Peter van Gelderen,et al.  Fast 3D functional magnetic resonance imaging at 1.5 T with spiral acquisition , 1996, Magnetic resonance in medicine.

[36]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[37]  Giuseppe Esposito,et al.  Dextroamphetamine Enhances “Neural Network-Specific” Physiological Signals: A Positron-Emission Tomography rCBF Study , 1996, The Journal of Neuroscience.

[38]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[39]  Streichenwein Sm,et al.  Am J Psychiatry , 1996 .

[40]  R. Murray,et al.  A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Schizophrenia Collaborative Linkage Group (Chromosome 22). , 1996, American journal of medical genetics.

[41]  M. Owen,et al.  No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. , 1996, The American journal of psychiatry.

[42]  R. Murray,et al.  Preferential transmission of the high activity allele of COMT in schizophrenia , 1996, Psychiatric genetics.

[43]  Karl J. Friston,et al.  A multivariate analysis of PET activation studies , 1996, Human brain mapping.

[44]  R. Straub,et al.  A potential vulnerability locus for schizophrenia on chromosome 6p24–22: evidence for genetic heterogeneity , 1995, Nature Genetics.

[45]  P S Goldman-Rakic,et al.  Spatial working memory deficits in the relatives of schizophrenic patients. , 1995, Archives of general psychiatry.

[46]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[47]  Richard Coppola,et al.  Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: A positron emission tomography study , 1995, Neuropsychologia.

[48]  S. Faraone,et al.  Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysis. , 1995, Journal of abnormal psychology.

[49]  I. Ulmanen,et al.  Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. , 1995, Biochemistry.

[50]  R. R. Abidin.  Psychological Assessment Resources , 1995 .

[51]  D. Housman,et al.  Follow-up of a report of a potential linkage for schizophrenia on chromosome 22q12-q13.1: Part 2. , 1994, American journal of medical genetics.

[52]  D. Housman,et al.  Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1. , 1994, American journal of medical genetics.

[53]  S. Faraone,et al.  Neuropsychological risk indicators for schizophrenia: a review of family studies. , 1994, Schizophrenia bulletin.

[54]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[55]  W. Ewens,et al.  Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). , 1993, American journal of human genetics.

[56]  Robert K. Heaton,et al.  Wisconsin Card Sorting Test Manual – Revised and Expanded , 1993 .

[57]  M C Speer,et al.  A microsatellite genetic linkage map of human chromosome 18. , 1993, Genomics.

[58]  R. Heaton.  Wisconsin Card Sorting Test manual , 1993 .

[59]  Douglas W. Jones,et al.  The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[60]  P. Goldman-Rakic,et al.  D1 dopamine receptors in prefrontal cortex: involvement in working memory , 1991, Science.

[61]  J. Ragland,et al.  Neuropsychological assessment of monozygotic twins discordant for schizophrenia. , 1990, Archives of general psychiatry.

[62]  J D Cohen,et al.  A network model of catecholamine effects: gain, signal-to-noise ratio, and behavior. , 1990, Science.

[63]  N. Risch.  Linkage strategies for genetically complex traits. I. Multilocus models. , 1990, American journal of human genetics.

[64]  D. Weinberger,et al.  Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. , 1988, Archives of general psychiatry.

[65]  T. Goldberg,et al.  Probing prefrontal function in schizophrenia with neuropsychological paradigms. , 1988, Schizophrenia bulletin.

[66]  D. Weinberger,et al.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. , 1986, Archives of general psychiatry.

[67]  G. H. Bush,et al.  Pharmacogenetics , 1968 .